Annabel Samimy
Stock Analyst at Stifel
(3.53)
# 870
Out of 5,055 analysts
49
Total ratings
47.83%
Success rate
35.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Buy | $60 → $80 | $82.11 | -2.57% | 2 | Sep 24, 2025 | |
| GPCR Structure Therapeutics | Initiates: Buy | $50 | $37.18 | +34.48% | 1 | Jan 8, 2025 | |
| ALT Altimmune | Initiates: Buy | $18 | $4.20 | +328.57% | 1 | Jan 8, 2025 | |
| IVA Inventiva | Maintains: Buy | $20 → $17 | $3.97 | +328.21% | 4 | Nov 22, 2024 | |
| MBX MBX Biosciences | Initiates: Buy | $40 | $24.67 | +62.14% | 1 | Oct 8, 2024 | |
| KMDA Kamada | Initiates: Buy | $18 | $7.01 | +156.96% | 1 | Jul 3, 2024 | |
| PHAT Phathom Pharmaceuticals | Initiates: Buy | $24 | $14.56 | +64.84% | 1 | May 3, 2024 | |
| RGNX REGENXBIO | Maintains: Buy | $40 | $11.84 | +237.84% | 2 | Apr 12, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Buy | $80 | $39.49 | +102.58% | 6 | Mar 15, 2024 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $225 → $230 | $142.76 | +61.11% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 → $25 | $7.45 | +235.80% | 1 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $19.72 | +77.48% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $65 | $20.61 | +215.38% | 3 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $700 → $275 | $8.85 | +3,007.34% | 4 | Jun 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $40.81 | +10.27% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $120 | $4.00 | +2,900.00% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.93 | +1,143.52% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $700 → $750 | $1.74 | +43,003.45% | 3 | Apr 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $24 | $45.55 | -47.31% | 7 | Apr 16, 2020 |
Palvella Therapeutics
Sep 24, 2025
Maintains: Buy
Price Target: $60 → $80
Current: $82.11
Upside: -2.57%
Structure Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $50
Current: $37.18
Upside: +34.48%
Altimmune
Jan 8, 2025
Initiates: Buy
Price Target: $18
Current: $4.20
Upside: +328.57%
Inventiva
Nov 22, 2024
Maintains: Buy
Price Target: $20 → $17
Current: $3.97
Upside: +328.21%
MBX Biosciences
Oct 8, 2024
Initiates: Buy
Price Target: $40
Current: $24.67
Upside: +62.14%
Kamada
Jul 3, 2024
Initiates: Buy
Price Target: $18
Current: $7.01
Upside: +156.96%
Phathom Pharmaceuticals
May 3, 2024
Initiates: Buy
Price Target: $24
Current: $14.56
Upside: +64.84%
REGENXBIO
Apr 12, 2024
Maintains: Buy
Price Target: $40
Current: $11.84
Upside: +237.84%
Viking Therapeutics
Mar 15, 2024
Reiterates: Buy
Price Target: $80
Current: $39.49
Upside: +102.58%
Jazz Pharmaceuticals
Mar 15, 2024
Maintains: Buy
Price Target: $225 → $230
Current: $142.76
Upside: +61.11%
Mar 8, 2024
Reiterates: Buy
Price Target: $23 → $25
Current: $7.45
Upside: +235.80%
Oct 5, 2023
Initiates: Buy
Price Target: $35
Current: $19.72
Upside: +77.48%
Aug 29, 2023
Maintains: Buy
Price Target: $60 → $65
Current: $20.61
Upside: +215.38%
Jun 26, 2023
Downgrades: Hold
Price Target: $700 → $275
Current: $8.85
Upside: +3,007.34%
Mar 7, 2023
Initiates: Buy
Price Target: $45
Current: $40.81
Upside: +10.27%
Nov 10, 2022
Upgrades: Buy
Price Target: $120
Current: $4.00
Upside: +2,900.00%
Aug 24, 2021
Initiates: Buy
Price Target: $24
Current: $1.93
Upside: +1,143.52%
Apr 16, 2020
Maintains: Buy
Price Target: $700 → $750
Current: $1.74
Upside: +43,003.45%
Apr 16, 2020
Maintains: Hold
Price Target: $25 → $24
Current: $45.55
Upside: -47.31%